Irinogenetics: How many stars are there in the sky?

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2578-2579

  Mathijssen, Ron H J ^a   Gurney, Howard ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CYTOCHROME P450 3A; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

DIARRHEA; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; EDITORIAL; ENZYME POLYMORPHISM; GENE; GENETIC RISK; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; UGT1A1 GENE; BIOTRANSFORMATION; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NOTE; PATIENT SELECTION; PHENOTYPE; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 66849136794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.2480     Document Type: Editorial

References (23)

1. 2009 ASCO Annual Meeting. www.asco.org/ASCO/Meetings/ASCO+Annual+Meeting
2. Innocenti F, Kroetz DL, Schuetz E, et al: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604-2614, 2009
3. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 25:4779-4786, 2007
4. Di Paolo A, Bocci G, Danesi R, et al: Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 1:311-323, 2006
5. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
6. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
7. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
8. Marcuello E, Altés A, Menoyo A, et al: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682, 2004
9. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007
10. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244, 2006
11. Innocenti F, Ratain MJ: "Irinogenetics" and UGT1A: From genotypes to haplotypes. Clin Pharmacol Ther 75:495-500, 2004
12. Mathijssen RH, Marsh S, Karlsson MO, et al: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253, 2003
13. Rosner GL, Panetta JC, Innocenti F, et al: Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther 84:393-402, 2008
14. Kweekel D, Guchelaar HJ, Gelderblom H: Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34:656-669, 2008
15. Toffoli G, Cecchin E, Corona G, et al: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006
16. Innocenti F, Janisch L, Das S, et al: A genotype-directed phase I study of irinotecan in advanced cancer patients. J Clin Oncol 25:97s, 2007 (suppl; abstr 2502)
17. van der Bol JM, Mathijssen RH, Loos WJ, et al: Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 25:2719-2726, 2007
18. Corona G, Vaccher E, Sandron S, et al: Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 83:601-606, 2008
19. Kharasch ED, Thummel KE, Watkins PB: CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv 5:151-153, 2005
20. Mathijssen RH, de Jong FA, van Schaik RH, et al: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592, 2004
21. Gao B, Klumpen HJ, Gurney H: Dose calculation of anticancer drugs. Expert Opin Drug Metab Toxicol 4:1307-1319, 2008
22. Mathijssen RH, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002
23. Levy S, Sutton G, Ng PC, et al: The diploid genome sequence of an individual human. PLoS Biol 5:e254, 2007